TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06533579: Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Sponsor: Vironexis Biotherapeutics Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,138,830

Unlock Full NCT06533579 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06533579 Rescue Dossier →